MINNEAPOLIS, June 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. announced the addition of a fifth regional sales manager, Steve Bowers, to complete the U.S. sales management team.
Mr. Bowers assumed his role as the South Central Regional Sales Manager last week. His depth of sales experience in the urology and urogynecology markets, his solid foundation in pelvic floor repairs and his long-term relationships with key physicians will enable him to quickly become a significant contributor to U.S. sales growth. David Kaysen, President and CEO, expressed enthusiasm for the capability of Mr. Bowers and of the entire U.S. sales management group. “Steve’s addition completes our current U.S. regional sales management organization. Our field sales managers, together with an expanding nationwide network of independent sales representatives, are a strong team with significant experience in the urology and gynecology markets. We are confident their focus, strategies and skills will facilitate rapid adoption and sales growth of our minimally invasive products for voiding dysfunctions -- the Urgent(R) PC Neuromodulation System and the I-STOP(TM) Mid-Urethral Sling.”
In accordance with American Stock Exchange rules, the Company also announced that it is granting Mr. Bowers options to purchase 10,000 shares of Uroplasty Common Stock as part of his compensation package. The exercise price for his options is equal to the closing price of the Company’s Common Stock on the American Stock Exchange on his start date of employment. These options are not under any of the Company’s stock option plans.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, overactive bladder and vesicoureteral reflux.
The Urgent(R) PC Neuromodulation System is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of overactive bladder. Uroplasty sells the Urgent PC system in the United States, in Canada and in countries recognizing the CE mark. Outside the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.
The I-STOP(TM) Mid-Urethral Sling is a biocompatible, tension-free sling used to treat female stress urinary incontinence. The I-STOP sling provides a hammock-like support for the urethra to prevent urine leakage associated with activities such as coughing, laughing, lifting or jumping. Uroplasty sells the I-STOP Sling in the United Kingdom and in the United States.
Macroplastique(R) Implants, Uroplasty’s patented soft tissue bulking agent, is used to treat both female and male urinary incontinence and to treat vesicoureteral reflux in children. When Macroplastique is injected into tissue, it stabilizes and “bulks” the tissue, providing the surrounding muscles with increased capability to control the flow of urine. Additionally, Uroplasty markets soft tissue bulking agents for specific indications such as PTQ(TM) Implants for the treatment of fecal incontinence, VOX(R) Implants for the treatment of vocal cord rehabilitation and Bioplastique(R) for augmentation or restoration of soft tissue defects in plastic surgery indications. Uroplasty’s bulking products are sold outside the United States.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words “aim,” “believe,” “expect,” “anticipate,” “intend,” “estimate” and other expressions, which indicate future events and trends, identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price.
FOR FURTHER INFORMATION: visit Uroplasty’s web page at http://www.uroplasty.com or contact Mr. Kaysen.
UROPLASTY, INC. David B. Kaysen, President / CEO 5420 Feltl Road Minnetonka, Minnesota 55343 Tel: 952.426.6140 Fax: 952.426.6199 E-mail: dave.kaysen@uroplasty.com
Uroplasty, Inc.
CONTACT: David B. Kaysen, President - CEO of Uroplasty, Inc.,+1-952-426-6140, or fax, +1-952-426-6199, or dave.kaysen@uroplasty.com
Web site: http://www.uroplasty.com/
